Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
Condition(s):Urinary Bladder Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Antineoplastic Agents; Urinary Bladder Diseases; Tislelizumab Antineoplastic Agents, ImmunologicalLast Updated:June 11, 2021Unknown status